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The world age-standardised prevalence of high-risk HPV (hrHPV) infection among 5038 UK women aged 20–59 years, with a low-
grade smear during 1999–2002, assessed for eligibility for TOMBOLA (Trial Of Management of Borderline and Other Low-grade
Abnormal smears) was 34.2%. High-risk HPV prevalence decreased with increasing age, from 61% at ages 20–24 years to 14–15% in
those over 50 years. The age-standardised prevalence was 15.1, 30.7 and 52.7%, respectively, in women with a current normal,
borderline nuclear abnormalities (BNA) and mild smear. In overall multivariate analyses, tertiary education, previous pregnancy and
childbirth were associated with reduced hrHPV infection risk. Risk of infection was increased in non-white women, women not
married/cohabiting, hormonal contraceptives users and current smokers. In stratified analyses, current smear status and age remained
associated with hrHPV infection. Data of this type are relevant to the debate on human papillomavirus (HPV) testing in screening and
development of HPV vaccination programmes.
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Infection with human papillomavirus (HPV) is necessary for the
development of cervical cancer (Walboomers et al, 1999; Bosch
et al, 2002). Around 40 HPV types infect mucosal surfaces of the
lower genital area (International Agency for Research on Cancer,
2005) and are broadly classified into high- or low-risk for cervical
cancer (Munoz et al, 2003). Testing for high-risk HPV (hrHPV)
DNA has the potential to improve cervical screening (Brink et al,
2005). In addition, following encouraging trial results (Harper
et al, 2004; Villa et al, 2005), two HPV vaccines are under licence.
The effectiveness and cost-effectiveness of incorporating HPV
testing into screening, and of vaccine programmes, will partly
depend on current HPV prevalence, infection patterns and factors
associated with infection within specific populations.
Human papillomavirus population prevalence mainly depends
on patterns of sexual exchange (International Agency for Research
on Cancer, 2005), which vary between and within countries, by, for
example, birth cohort and ethnic group (Johnson et al, 2001;
Fenton et al, 2005). Most available data on HPV prevalence and
associated factors are from the United States of America, and/or
focus on young women; many series are highly selective and may
lack generalisibility. Other series did not examine lifestyle risk
factors (e.g. Cuzick et al, 2003; Cuschieri et al, 2004; Moss et al,
2004; Hibbitts et al, 2006; Kitchener et al, 2006). Most infections in
women under 30 are transient (Koutsky and Kiviat, 1999;
Nobbenhuis et al, 2001; Woodman et al, 2001); infection risk
factors, and/or their relative importance, may differ between young
and older women. In addition, while cytological smear grade is
strongly associated with HPV prevalence (Cuzick et al, 2003;
Cuschieri et al, 2004), it is less clear whether the relative
contribution of lifestyle risk factors differs by smear grade. We
investigated factors associated with prevalence of hrHPV types in a
large series of UK women and compared them in younger and
older women and by cytological smear grade.
MATERIALS AND METHODS
Study population
Subjects were women assessed for eligibility for TOMBOLA
(Trial Of Management of Borderline and Other Low-grade
Abnormal smears), a randomised controlled trial (RCT) of
alternative management policies and HPV triage (TOMBOLA
Group, 2006).
Women aged 20–59 years, resident in Grampian, Tayside or
Nottingham, with a low-grade smear (mild dyskaryosis or
borderline nuclear abnormalities (BNA)) taken routinely in the
UK national cervical screening programmes (CSPs) during 01/10/
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were eligible for TOMBOLA. Recruitment was in two phases: 01/
10/1999–12/03/2001 and 13/03/2001–31/10/2003. During phase
one, eligible women had no abnormal smears in the previous 3
years; during phase two, they had up to one BNA smear in the
previous 3 years. In phase one, women with a BNA smear were
invited to a recruitment clinic approximately 6 months later for a
follow-up smear and a swab for HPV testing. Women with a mild
smear during both phases, or a BNA smear during phase two, were
invited to a recruitment clinic approximately 2 months later and a
swab for HPV testing was taken. The swab, an endocervical
sample, was taken with a cytobrush; this was immersed in 2ml of
sterile phosphate-buffered saline containing 0.05% thiomersal.
A total of 52% of eligible women attended a recruitment clinic,
of whom 95% (n¼5514) consented to participate; 27 were
subsequently excluded because the smear was inadequate. Five
thousand and seventy-four (92%) of the remainder provided an
HPV sample.
Ethical approval was obtained from the joint Research Ethics
Committee of NHS Grampian and the University of Aberdeen, the
Tayside Committee on Medical Research Ethics and the Notting-
ham Research Ethics Committee. Participants provided informed
consent.
HPV testing
Analysis was performed 1–4 weeks after swab collection in a single
laboratory (Nottingham). Human and viral DNA were extracted
using the Qiagen UK kit (Crawley, West Sussex, UK) (QIAamp
s
DNA Mini Kit) following optimisation of the manufacturer’s
protocol. Each batch included negative controls containing only
elution buffer AE. Extracted DNA was amplified and quantitated
by type-specific real-time polymerase chain reaction (PCR) for the
housekeeping gene, human betaglobin. Samples without record-
able DNA levels were considered inadequate (n¼36; 0.7% of
5074). Adequate samples underwent HPV PCR using GP5þ/6þ
consensus primers, followed by enzyme immunoassay for detec-
tion of 14 high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 66 and 68) (Jacobs et al, 1997). Women were considered hrHPV
positive (hrHPVþve) if their sample had an optical density (OD)
three times greater than that of the batch-negative control,
implying they carried at least one of the hrHPV strains. Other
women were classified hrHPV negative (hrHPV ve). Information
was not available on individual HPV strains.
Questionnaire
At recruitment, all women completed a questionnaire on ethnic
group, marital status, tertiary education, employment, reproduc-
tive factors, smoking and physical activity.
Statistical analysis
Women were classified by smear status, defined by their ‘current’
smear and any past BNA smear. For women with a BNA smear
during recruitment phase one, this was considered the ‘past’
smear, while the ‘current’ smear was the recruitment smear
(results ranged from normal to severe dyskaryosis). For other
women, the ‘current’ smear was the smear that triggered the
invitation to participate in TOMBOLA. Six smear status categories
were defined: normal and one previous BNA; BNA and no previous
abnormal; BNA and one previous BNA; mild and no previous
abnormal; mild and one previous BNA; and moderate or severe
dyskaryosis and one previous BNA.
Socio-demographic characteristics of women providing, and not
providing, an HPV sample were compared using w
2-tests. High-
risk HPV prevalence was age-standardised to the truncated (20–59
years) world standard population. Multivariate unconditional
logistic regression models were constructed to assess factors
associated with hrHPVþve risk. Since age modified the relation-
ship between smear status and hrHPV status, these factors were
fitted by a single variable, which combined the six smear status
categories with two age groups (20–29 and X30 years). The global
likelihood ratio test (LRT) was used to assess the impact of lifestyle
and socio-demographic factors on age-and-smear status-adjusted
risk estimates; factors with Po0.1 were retained in the final model.
To explore sub-group heterogeneity, the modelling was repeated
stratifying by age (20–29 years; X30 years) and current smear
(normal; BNA; mild). All multivariate models had adequate fit (by
the Hosmer and Lemeshow test; Hosmer and Lemeshow, 1989).
RESULTS
Younger women, white women and those with a single BNA or
mild smear were less likely to provide an HPV sample than older
women (w3
2¼8.30, P¼0.040), non-white ethnic groups (w1
2¼8.19,
P¼0.004) or those with a previous abnormal smear (w5
2¼100.85,
Po0.001). Since two of three centres did not take swabs from
menstruating women, the proportion providing a sample varied by
centre (w2
2¼294.53, Po0.001). It did not vary by tertiary education
level (w1
2¼0.34, P¼0.559).
The crude hrHPV prevalence was 39.2% (95% confidence
interval (CI) 37.8–40.5). Positivity declined with increasing age
(20–24 years 61.0%, 25–29 years 50.1%, 30–34 years 39.6%, 35–
39 years 30.6%, 40–44 years 22.0%, 45–49 years 17.1% and 50–59
years 14–15%), and increased with increasing smear grade. For all
grades, prevalence and risk were higher in younger (20–29 years)
than older (X30 years) women, but not by a constant amount
(Figure 1; P(interaction) 0.0004). The overall age-standardised
prevalence was 34.2% (95% CI 32.6–35.8). For women with a
current normal smear, it was 15.1% (95% CI 12.6–17.6), for those
with a current BNA smear 30.7% (95% CI 8.6–32.8) and with a
current mild smear 52.7% (95% CI 48.6–56.8).
Other factors significantly associated with hrHPV status in
multivariate analyses were tertiary education level, ethnic group,
marital status, reproductive history, hormonal contraceptive use
and smoking (Table 1). Women with a college/university degree
were at reduced hrHPVþve risk compared with those without a
degree. Although prevalence varied little by ethnic group, in
multivariate analyses, non-white women (e.g. black-African,
Indian, Pakistani) were at significantly increased risk. Single, and
divorced/separated/widowed, women had significantly higher
infection risk than married/co-habiting women. High-risk HPV
infection was associated with never being pregnant, having had
children and age at first pregnancy, but not with number of
children or caesarean delivery. Combining pregnancy, childbirth
and age at first pregnancy (as ‘reproductive history’), having a
pregnancy resulting in childbirth was associated with lower
infection risk, particularly for a first pregnancy at age X20 years.
Current and previous oral contraceptive (OC) use (combined or
progesterone-only), and current use of other hormonal contra-
ception (e.g. implants, injections, intrauterine system), were
associated with increased risk. Compared with never smokers,
current smokers (but not ex-smokers) were at a modest increased
risk, unrelated to smoking pack-years (data not shown). Barrier
contraception and physical activity were also unrelated to risk.
In multivariate age-stratified analyses of women aged 20–29
years, age and smear status were significantly associated with
infection. Tertiary education and having had children were also
significant risk factors, with risk estimates similar to those in
unstratified analyses. In women aged 30–59 years, age and smear
status were significantly associated with infection, as were tertiary
education, having had children, ethnicity and smoking; effect sizes
were similar to those in Table 1. Other significant factors were
marital status (increased risk in divorced/separated/widowed
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ywomen (odds ratio (OR) 2.23, 95% CI 1.79–2.79) and single
women (OR 1.84, 95% CI 1.35–2.50)), current hormonal contra-
ceptive use (OR user vs non-user 1.30, 95% CI 1.03–1.64) and
physical activity (OR active vs not active 0.76, 95% CI 0.60–0.97).
In multivariate smear-stratified analyses of all smear groups, age
was significantly associated with infection. Having a college/
university degree reduced infection risk in women with a current
normal (OR 0.58, 95% CI 0.34–0.99) or BNA smear (OR 0.72, 95%
CI 0.56–0.91) but not in those with a mild smear. In all smear
strata, divorced/separated/widowed women had higher risk than
married/co-habiting women (normal OR 1.64, 95% CI 0.91–2.96;
BNA OR 2.26, 95% CI 1.73–2.95; mild OR 2.12, 95% CI 1.49–3.02).
In the BNA strata only, being single also increased risk (OR 1.34,
95% CI 1.06–1.70). Having been pregnant was inversely associated
with infection in those with a current normal (OR 0.60, 95% CI
0.38–0.95) or BNA smear (OR 0.81, 95% CI 0.64–1.02), but not in
those with a mild smear. Having had children was associated with
reduced risk in all smear strata, only reaching statistical
significance in the current normal group (OR 0.57, 95% CI 0.36–
0.92). Hormonal contraceptive use was associated with increased
risk in the current normal (OR 1.59, 95% CI 1.02–2.48) and BNA
(OR 1.29, 95% CI 1.05–1.59) strata, but not among the mild group.
Barrier contraceptive use, caesarean delivery, smoking, physical
activity and ethnicity were unrelated to infection in all strata.
DISCUSSION
Our study was large, population-based and nested in a pragmatic
RCT within the UK national CSPs. Among study participants, the
current BNA:mild smear ratio (1.8:1) was close to that reported
for the CSP screening age group in 2004–2005 (1.9:1) (NHS
Health and Social Care Information Centre, 2005; ISD Scotland,
2007), suggesting our results are likely to be generalisable to
women with low-grade smears.
While TOMBOLA participation was 52% overall, it was lower
among younger women and those resident in more deprived areas
(TOMBOLA Group, 2006), groups with increased HPV prevalence
in this and other studies (Tonon et al, 1999; Cuzick et al, 2003;
Winer and Koutsky, 2004). Thus, our crude hrHPV prevalence is
likely to somewhat underestimate true prevalence among women
with low-grade smears.
The treatment of lesions, and possibly also the act of taking a
smear, can potentially clear cervical HPV infection (Shapiro et al,
2003; Sarian et al, 2005). Thus, hrHPV prevalence may be
artificially lowered in populations with extensive screening cover-
age, such as the UK. Our participants had no previous treatment
for cervical lesions and 66% had their last smear X3 years before
becoming eligible for TOMBOLA. Since hrHPV infection averages
8–14 months (Ho et al, 1998; Woodman et al, 2001), the effect of
screening participation on our prevalence estimate is probably
small.
A limitation of our study is that we did not collect information
on numbers of sexual partners, age at first intercourse, etc, because
of CSP guidelines (Duncan, 1997). Some factors we found to be
associated with hrHPV infection may be markers of sexual
behaviour. For example, smoking is associated with having had
multiple sexual partners (Osler and Kjaer, 1996; Escobedo et al,
1997; Lam et al, 2001; Bellis et al, 2004; Jarvelaid, 2004), which is
consistent with the observed raised infection risk among current
smokers. UK rates of new partner acquisition vary by marital
status, being highest among single or previously married women,
intermediate among co-habiting women and lowest in married
women (Johnson et al, 2001), a pattern compatible with our
findings.
Our analyses extend existing knowledge on UK hrHPV
prevalence, and are novel for Grampian and Tayside. Data from
this and similar analyses will aid interpretation of studies of HPV
testing in screening (e.g. Kitchener et al, 2006), and be valuable in
modelling scenarios for alternative screening protocols, including
HPV testing, as well as for policy makers in defining HPV
vaccination strategies. It also provides a baseline against which the
impact of vaccination on HPV infection patterns can be assessed in
the future.
Smear status
Other than age, current smear grade was the strongest predictor of
infection. In women with a current BNA smear, our hrHPV
prevalence (crude 34.2%, age-standardised 30.7%) was similar to
that among women with a BNA smear from the UK ARTISTIC trial
(31%) (Kitchener et al, 2006), but lower than (unstandardised)
frequencies from other UK studies (46%; Moss et al, 2004, B55%;
Hibbitts et al, 2006, 72%; Cuschieri et al, 2004), and for women
with ASCUS (atypical cells of undetermined significance) smears
from the US ALTS trial (49%; ALTS Group 2003). In the UK HART
study, HPV prevalence among 289 women aged 30–60 years with a
current BNA smear was 27% (Cuzick et al, 2003), close to the crude
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Figure 1 hr HPV positivity (%) by smear status and age. BNA, smear showing BNA; mild, smear showing mild dyskaryosis; worse than mild, smear
showing moderate or severe dyskaryosis; single BNA, women with a current BNA smear and no other BNA smear in previous 3 years; single mild, women
with a current mild smear and no BNA smear in previous 3 years. Adjusted OR: adjusted for age (in women aged 30 years or over – 30–34, 35–59, 40–44,
45–49, 50–54 and 55–59 years; in women aged less than 30 years – 20–24 and 25–29 years).
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yTable 1 Numbers and proportions of women hrHPV+ve and adjusted multivariate ORs for socio-demographic and lifestyle factors
Total (n) hr HPV+ve (n) % hrHPV+ve Multivariate OR
a 95% CI
Overall 5038 1973 39.2
Tertiary education/training
No degree 4122 1656 40.2 1 Reference
Degree 887 305 34.4 0.72 0.61–0.87
Missing 29 12 41.4
Global w1
2¼12.85, P¼0.0003
Ethnicity
White 4787 1868 39.0 1 Reference
Other (non-white) 223 95 42.6 1.42 1.03–1.94
Missing 28 10 35.7
Global w1
2¼4.68, P¼0.0306
Marital status
Married/living as married 2824 840 29.8 1 Reference
Divorced/separated/widowed 667 289 43.3 1.97 1.62–2.40
Single 1494 826 55.3 1.29 1.09–1.53
Missing 53 18 34.0
Global w2
2¼47.80, Po0.0001
Ever pregnant
b
No 1589 855 53.8 1 Reference
Yes 3412 1104 32.4 0.75 0.63–0.89
Missing 37 14 37.8
Global w1
2¼11.30, P¼0.0008
Age at first pregnancy
b
Never pregnant 1589 855 53.8 1 Reference
First pregnancy aged o20 years 1080 453 41.9 0.86 0.71–1.05
First pregnancy aged over 20 years 2303 640 27.8 0.67 0.55–0.80
Missing 66 25 37.9
Global w2
2¼19.76, P¼0.0001
Children
b
No 2113 1096 51.9 1 Reference
Yes 2869 854 29.8 0.71 0.60–0.83
Missing 56 23 41.1
Global w1
2¼17.06, Po0.0001
Number of children
b,c
1 793 324 40.9 1 Reference
2 1170 288 24.6 0.75 0.59–0.95
3 563 148 26.3 0.89 0.67–1.19
4 190 49 25.8 0.82 0.54–1.24
5–8 86 25 29.1 1.11 0.64–1.94
Missing 67 20 29.9
Global w4
2¼7.23, P¼0.1242
Caesarean ever
b,c
No 2367 704 29.7 1 Reference
Yes 481 145 30.2 1.12 0.88–1.43
Missing 21 5 23.8
Global w1
2¼0.85, P¼0.3574
Reproductive history
d
Never pregnant 1589 855 53.8 1 Reference
First pregnancy oage 20 years, have children 867 335 38.6 0.79 0.64–0.99
First pregnancy oage 20 years, no children 205 113 55.1 1.01 0.73–1.40
First pregnancy Xage 20 years, have children 1981 513 25.9 0.61 0.50–0.75
First pregnancy Xage 20 years, no children 313 125 39.9 0.83 0.62–1.10
Missing 83 32 38.6
Global w4
2¼25.55, Po0.0001
Current barrier contraception
No 4211 1611 38.3 1 Reference
Yes 811 354 43.7 1.05 0.87–1.27
Missing 16 8 50.0
Global w1
2¼0.29, P¼0.5907
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prevalence estimate among women with a current mild smear
(crude 60.9%, age-standardised 52.7%) was also lower than non-
standardised estimates from the United Kingdom and the United
States of America of at least 70% (ALTS Group 2003; Moss et al,
2004; Hibbitts et al, 2006; Kitchener et al, 2006). In addition to
different age profiles, comparison between studies is complicated
by different HPV testing regimes (since tests detect different
strains and vary in performance characteristics; Kulmala et al,
2004; Bosch and Iftner, 2005) and UK/USA differences in
cytological abnormality classification.
Our crude (16.0%) and age-standardised (15.1%) prevalences
among women with a current normal smear were similar to the
pooled estimate from 27 PCR-based studies of cytologically normal
women mainly from North America and Europe (16.2%) (Xi and
Koutsky, 1997). However, our figures were higher than in recent
UK screening studies with normal cytology reporting unstandar-
dised frequencies of 6–10% (Cuzick et al, 2003; Cuschieri et al,
2004; Hibbitts et al, 2006; Kitchener et al, 2006). Our participants
had had a previous BNA smear, which might inflate hrHPV
prevalence, although among women with a current low-grade
smear, having a previous BNA smear did not substantially increase
prevalence (single BNA 34%; BNA/BNA 35%; single mild 60%;
BNA/mild 69%). Our crude prevalence among women aged 30–59
years (8.4%) was similar to that from the HART study (6%)
(Cuzick et al, 2003). Our age-standardised prevalence was similar
to that for sexually active women aged 15–74 years from four
countries in Latin America (12.4–17.7%) and parts of Asia (China,
Korea, India; 14.0–16.8%), higher than for Vietnam and Thailand
(1.6–11.4%) and lower than for Nigeria (27.0%) (Franceschi et al,
2006); these figures relate to 27 HPV types, including 6 and 11.
Age
Notable geographical variations in age-specific HPV curves have
recently been described (Franceschi et al, 2006). Our observation
of decreasing hrHPV infection with increasing age (in all smear
strata) is consistent with other UK, European and US series
(Cuzick et al, 2003; Winer and Koutsky, 2004; Franceschi et al,
2006; Hibbitts et al, 2006).
Ethnic group
In the United Kingdom, white, black-African and black-Caribbean
women have higher numbers of lifetime sexual partners, lower
median age at first heterosexual intercourse and higher incidence
of (non-HPV) sexually transmitted infections than women from
Indian or Pakistani ethnic groups (Fenton et al, 2005). Although
we observed increased infection risk among non-white ethnic
groups, relatively few women described themselves thus (n¼223),
precluding multivariate analysis of individual groups. Crude
infection frequencies (Asian origin 35%; white 39%; black 45%)
are consistent with sexual behaviour data and suggest that the
raised risk may be limited to black women.
Contraception
High-risk HPV infection risk was 450% higher in women who had
used OCs or other hormonal contraceptives. The latter have been
studied little previously. Among ALTS participants, no association
was found with injectable contraceptives or Norplant (Castle et al,
2005). Previous studies of OC use have been inconsistent (Green
et al, 2003; Winer and Koutsky, 2004; Vaccarella et al, 2006a),
perhaps due to differences in study design, types of OCs used/
assessed, prevalence of use and adjustment factors. While OC use
may simply be a marker for ‘high-risk’ sexual behaviours (Winer
and Koutsky, 2004), in several studies the OC–hrHPV association
persisted after adjustment for factors such as number of sexual
partners (Ley et al, 1991; Sikstrom et al, 1995; Winer et al, 2003). In
further analyses, we found a stronger relationship between current,
than past, OC use and hrHPV positivity (OR ex-users vs never users
1.23 (95% CI 0.99–1.51); OR current users vs never users 1.46 (95%
Table 1 (Continued)
Total (n) hr HPV+ve (n) % hrHPV+ve Multivariate OR
a 95% CI
Hormonal contraception
e
Never pill user/no other current hormonal contraception 2416 649 26.9 1 Reference
Never pill user/currently use other hormonal contraception 200 101 50.5 1.58 1.13–2.21
Ex-pill user/no other current hormonal contraception 551 256 46.5 1.33 1.06–1.66
Ex-pill user/currently use other hormonal contraception 98 48 49.0 1.12 0.71–1.76
Current pill 1694 889 52.5 1.54 1.30–1.84
Missing 79 30 38.0
Global w4
2¼27.33, Po0.0001
Physical activity
f
Never 720 275 38.2 1 Reference
Ever 4239 1665 39.3 0.86 0.71–1.04
Missing 79 33 41.8
Global w1
2¼2.40, P¼0.1216
Smoking status
Never smoker 2340 862 36.8 1 Reference
Ex-smoker 851 264 31.0 0.88 0.73–1.07
Current smoker 1798 822 45.7 1.21 1.04–1.40
Missing 49 25 51.0
Global w2
2¼11.83, P¼0.0027
Abbreviations: CI, confidence interval; hrHPV+ve, hrHPV positive; OR, odds ratio.
aMultivariate OR adjusted for age/smear, tertiary education/training, ethnicity, marital status,
reproductive history, use of hormonal contraception and smoking status.
bMultivariate OR adjusted for age/smear, tertiary education/training, ethnicity, marital status, use of
hormonal contraception and smoking status.
cRestricted to women who have had children.
dEver been pregnant, age at first pregnancy and ever had children were all individually
associated with hrHPV. As these variables are related, a composite variable was created and fitted in model.
eWomen were classified into one of five categories on the basis of
current use of oral contraceptive pill or other hormonal contraception, and on any previous oral contraceptive pill use.
fThere was no effect on risk of hrHPV of physical activity
(never/ever) or of frequency of physical activity (data not shown).
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mechanisms by which current OC use influences infection, which
include the enhancing effect of oestrogens on cervical ectopy,
thereby permitting potential carcinogens (including HPV) easier
access to the transformation zone (Green et al, 2003), and increased
cell proliferation and transcription of HPV induced by direct
hormonal effects on cervical cells (de Villiers, 2003).
Reproductive history
Our observation that having been pregnant was associated with
reduced hrHPV infection risk is consistent with the IARC HPV
Prevalence Surveys Study Group analysis of 415000 women
(Vaccarella et al, 2006a). We found that the effect was stronger if a
childbirth had resulted, and with older age at first pregnancy. In
the United Kingdom, earlier age at first pregnancy or childbirth,
and decreased likelihood of having an abortion, are associated with
low socio-economic status (Smith, 1993; Wellings et al, 2001; ISD
Scotland, 2006). However, our analysis was adjusted for tertiary
education as a measure of socio-economic status. Although age at
first pregnancy may be a marker for age at sexual debut, it is not as
strongly predictive of HPV infection as previously thought
(Vaccarella et al, 2006b). Possible explanations for this inverse
association with pregnancy include breastfeeding, which results in
high progesterone levels with atrophic changes and retraction of
the squamocolumnar junction into the cervical canal, possibly
reducing the likelihood of infection; alterations in patterns of
sexual (e.g. changing partners, frequency of coitus) and other
behaviours that influence infection risk (e.g. smoking).
Age- and smear-stratified analyses
Identifying differences in the relative importance of risk factors in
sub-groups can be informative – as is evident from the few
previous studies using this analytical approach (Lazcano-Ponce
et al, 2001; Molano et al, 2002; Anh et al, 2003). We undertook age-
and smear-stratified analyses because these were the most
important risk factors, and they interacted, suggesting that the
relative contribution of hrHPV infection, and other factors, in the
aetiology of cytological abnormalities differs by age.
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